Inventor · disambiguated record
Dalton King
Also filed as: KING DALTON
19 granted patents·16 pending applications·801 citations·filing 1996–2020
95Inventor score
Top patents by PatentIndex Score
35 records- 0198US5824805ABranched hydrazone linkersFiled 1996·Granted Oct 20, 1998·417 cites·13 claims
- 0296US6759509B1Branched peptide linkersBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Jul 6, 2004·217 cites·35 claims
- 0391US7863291B2Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Jan 4, 2011·22 cites·14 claims
- 0489US9221796B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Dec 29, 2015·5 cites·12 claims
- 0587US10933069B2Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissuesCYBREXA 1 INC·Filed 2019·Granted Mar 2, 2021·6 cites·29 claims
- 0687US8309577B2Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligandsCOOK II JAMES H·Filed 2009·Granted Nov 13, 2012·10 cites·18 claims
- 0783US7105516B2Compounds for the treatment of premature ejaculationBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 12, 2006·15 cites·59 claims
- 0883US6512101B1Branched hydrazone linkersBRISTOL MYERS SQUIBB CO·Filed 1998·Granted Jan 28, 2003·55 cites·9 claims
- 0977US6777437B2Cyclopropylindole derivatives as selective serotonin reuptake inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Aug 17, 2004·12 cites·36 claims
- 1076US8507516B2Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligandsMCDONALD IVAR M·Filed 2010·Granted Aug 13, 2013·4 cites·3 claims
- 1175US8278320B2Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligandsMCDONALD IVAR M·Filed 2010·Granted Oct 2, 2012·4 cites·14 claims
- 1274US8481555B2Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugsLENTZ KIMBERLEY A·Filed 2011·Granted Jul 9, 2013·6 cites·9 claims
- 1373US8722670B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2012·Granted May 13, 2014·2 cites·13 claims
- 1473US2021121453A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1571US6613786B2Thiophenyl triazol-3-one derivatives as smooth muscle relaxantsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Sep 2, 2003·5 cites·21 claims
- 1669US2020163949A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1769US2019314358A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 1868US2019117638A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1966US2015094309A1Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 2066US2018250283A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 2165US7049314B2Cyclopentyl indole derivativesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 23, 2006·3 cites·48 claims
- 2265US2014221377A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 2365US2018000807A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 2465US2018110766A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 2564US5939405APhosphate derivatives of diaryl 1,3,4-oxadiazoloneBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Aug 17, 1999·18 cites·9 claims
- 2664US2017258777A1Selective NR2B AntagonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 2762US2013131064A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 2859US2016101104A1Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 2959US2016081995A1Selective NR2B AntagonistsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3058US2015342935A1Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligandsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3156US12427157B2Methods for treatment of diseases involving acidic or hypoxic diseased tissuesCYBREXA 1 INC·Filed 2020·Granted Sep 30, 2025·0 cites·29 claims
- 3256US2012035178A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsCOOK II JAMES H·Filed 2011·Application pending·0 cites
- 3356US2012035189A1Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor LigandsCOOK II JAMES H·Filed 2011·Application pending·0 cites
- 3442US8841301B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Sep 23, 2014·0 cites·10 claims
- 3537US7977362B2Alpha-(N-benzenesulfonamido)cycloalkyl derivativesBRISTOL MYERS SQUIBB CO·Filed 2010·Granted Jul 12, 2011·0 cites·31 claims
Join the waitlist — get patent alerts
Get an alert when Dalton King files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →